| 32 | 0 | 282 |
| 下载次数 | 被引频次 | 阅读次数 |
呼吸道合胞病毒（Respiratory syncytial virus,RSV）是引起婴幼儿急性下呼吸道感染的主要病原体，给全球公共卫生带来了严峻挑战。尽管RSV感染带来的疾病负担十分沉重，目前针对RSV感染的治疗和预防手段仍然相对有限，但近期的研究进展为该领域带来了新的希望。目前已有两种RSV特异性疫苗和一种单克隆抗体获得批准，同时新型抗病毒药物的研发也取得了突破，但不适用于儿童。这些成果不仅为减轻RSV感染的影响提供了新的治疗选择，也为未来的预防策略奠定了基础。然而，开发针对儿童的RSV疫苗和药物，以及提高公众对疫苗接种的认识和接受度，依然是亟待解决的问题。本文全面探讨了RSV感染的预防与治疗策略，旨在为未来RSV的防控工作提供科学依据和参考。
Abstract：Respiratory syncytial virus(RSV) is a leading cause of acute lower respiratory tract infection(LRTI) in infants and young children and represents a substantial global public health burden. Despite this, available options for the prevention and treatment of RSV infection remain limited. Recent advances, however, have brought renewed momentum to the field. To date, two RSV-specific vaccines and one monoclonal antibody have been approved, and significant progress has been made in the development of novel antiviral agents, although their use in pediatric populations remains limited. These developments not only provide new therapeutic options to mitigate the clinical impact of RSV infection but also lay the foundation for improved preventive strategies. Nevertheless, the development of safe and effective vaccines and antiviral agents for children, along with improved public awareness and acceptance of vaccination, remains a critical unmet need. This review comprehensively summarizes current prevention and treatment strategies for RSV infection and aims to provide a scientific basis for future control and management efforts.
[1]郑海涛，丁樱，任献青，等.人呼吸道合胞病毒感染对机体相关免疫应答影响的研究进展[J].病毒学报，2022, 38(3):724-730. DOI:10. 13242/j. cnki.bingduxuebao. 004096.
[2]张心悦，吴芳，聂晶，等.呼吸道合胞病毒感染的免疫致病机制研究进展[J].病毒学报，2025, 41(1):222-231. DOI:10. 13242/j. cnki. bingduxuebao. 004567.
[3]Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019:a systematic analysis[J]. Lancet, 2022, 399(10340):2047-2064.DOI:10. 1016/S0140-6736(22)00478-0.
[4]Binns E, Tuckerman J, Licciardi PV, et al. Respiratory syncytial virus, recurrent wheeze and asthma:a narrative review of pathophysiology, prevention and future directions[J]. J Paediatrics Child Health, 2022,58(10):1741-1746. DOI:10. 1111/jpc. 16197.
[5]Shi T, Denouel A, Tietjen AK, et al. Global disease burden estimates of respiratory syncytial virus–associated acute respiratory infection in older adults in2015:a systematic review and meta-analysis[J]. J Infect Dis, 2020, 222(Supplement_7):S577-S583.DOI:10. 1093/infdis/jiz059.
[6]Li Y, Johnson EK, Shi T, et al. National burden estimates of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in 2019 among 58 countries:a modelling study[J]. Lancet Respir Med, 2021, 9(2):175-185. DOI:10. 1016/S2213-2600(20)30322-2.
[7]浙江省疾病预防控制中心，浙江省传染病疫苗与预防控制研究重点实验室，国家儿童医学中心（上海）复旦大学附属儿科医院，等.人呼吸道合胞病毒感染监测与防控专家共识（2023年）[J].中华临床感染病杂志，2023, 16(5):337-353. DOI:10. 3760/cma. j.issn. 1674-2397. 2023. 05. 002.
[8]Bont L. Nosocomial RSV infection control and outbreak management[J]. Paediatr Respir Rev, 2009, 10:16-17. DOI:10. 1016/S1526-0542(09)70008-9.
[9]中国医药教育协会儿科专业委员会，中华医学会儿科学分会呼吸学组，中国医师协会呼吸医师分会儿科呼吸工作委员会，等.中国儿童呼吸道合胞病毒感染诊疗及预防指南（2024医生版）[J].中华实用儿科临床杂志，2024, 39(10):723-732. DOI:10. 3760/cma. j.cn101070-20240828-00545.
[10]Ozturk A, Chan M, Khan J R, et al. Clinical characteristics and in-hospital outcomes associated with RSV-ALRI compared to other viral ALRI in hospitalised children under two years old[J]. J Infect Dis, 2024. DOI:10. 1093/infdis/jiae543.
[11]Zhao C, Bai Y, Wang W, et al. Activation of STAT3-mediated ciliated cell survival protects against severe infection by respiratory syncytial virus[J]. J Clin Investig, 2024, 134(21):e183978. DOI:10. 1172/jci183978.
[12]Domachowske JB, Anderson EJ, Goldstein M. The future of respiratory syncytial virus disease prevention and treatment[J]. Infect Dis Ther, 2021, 10(1):47-60. DOI:10. 1007/s40121-020-00383-6.
[13]Gatt D, Martin I, AlFouzan R, et al. Prevention and treatment strategies for respiratory syncytial virus(RSV)[J]. Pathogens, 12(2):154. DOI:10. 3390/pathogens12020154.
[14]Anderson LJ. Respiratory syncytial virus vaccine development[J]. Semin Immunol, 2013, 25(2):160-171. DOI:10. 1016/j. smim. 2013. 04. 011.
[15]Mufson MA, Orvell C, Rafnar B, et al. Two distinct subtypes of human respiratory syncytial virus[J]. J Gen Virol, 1985, 66(10):2111-2124. DOI:10. 1099/0022-1317-66-10-2111.
[16]胡宏俏，李海，黄星湖，等.人呼吸道合胞病毒F蛋白多肽免疫原性的初步研究[J].病毒学报，2023, 39(2):344-353.
[17]Progress at last against RSV[J]. Nature Medicine,2023, 29(9):2143-2143. DOI:10. 1038/s41591-023-02571-6.
[18]Melgar M, Britton A, Roper LE, et al. Use of respiratory syncytial virus vaccines in older adults:recommendations of the advisory committee on immunization practices—United States, 2023[J]. Am J Transplant, 2023, 23(10):1631-1640. DOI:10. 1016/j. ajt. 2023. 09. 003.
[19]Kampmann B, Madhi SA, Munjal I, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants[J]. N Engl J Med, 2023, 388(16):1451-1464. DOI:10. 1056/NEJMoa2216480.
[20]Committee On Infectious Diseases And Bronchiolitis Guidelines Committee, Brady MT, Byington CL, et al. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection[J]. Pediatrics, 2014, 134(2):415-420. DOI:10. 1542/peds. 2014-1665.
[21]Sparrow E, Adetifa I, Chaiyakunapruk N, et al. WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus(RSV)disease in infants–Key considerations for global use[J]. Vaccine, 2022, 40(26):3506-3510. DOI:10. 1016/j.vaccine. 2022. 02. 040.
[22]Shang Z, Tan S, Ma D. Respiratory syncytial virus:from pathogenesis to potential therapeutic strategies[J].Int J Biol Sci, 2021, 17(14):4073-4091. DOI:10. 7150/ijbs. 64762.
[23]Wu H, Pfarr DS, Johnson S, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract[J]. J Mol Biol, 2007,368(3):652-665. DOI:10. 1016/j. jmb. 2007. 02. 024.
[24]Griffin MP, Yuan Y, Takas T, et al. Single-dose nirsevimab for prevention of RSV in preterm infants[J].N Engl J Med, 2020, 383(5):415-425. DOI:10. 1056/nejmoa1913556.
[25]Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants[J]. N Engl J Med, 2022, 386(9):837-846.DOI:10. 1056/nejmoa2110275.
[26]Jones JM, Fleming-Dutra KE, Prill MM, et al. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children:recommendations of the advisory committee on immunization practices—United States, 2023[J].MMWR Morb Mortal Wkly Rep, 2023, 72(34):920-925. DOI:10. 15585/mmwr. mm7234a4.
[27]Colosia A, Costello J, McQuarrie K, et al. Systematic literature review of the signs and symptoms of respiratory syncytial virus[J]. Influenza Resp Viruses,2023, 17(2):e13100. DOI:10. 1111/irv. 13100.
[28]Bonneux B, Jacoby E, Ceconi M, et al. Direct-acting antivirals for RSV treatment, a review[J]. Antivir Res,2024, 229:105948. DOI:10. 1016/j.antiviral. 2024. 105948.
[29]Trang TP, Whalen M, Hilts-Horeczko A, et al.Comparative effectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections:a single-center retrospective cohort study and review of the literature[J]. Transpl Infect Dis, 2018, 20(2):e12844. DOI:10. 1111/tid. 12844.
[30]Sim?es EAF, Bont L, Manzoni P, et al. Past, present and future approaches to the prevention and treatment of respiratory syncytial virus infection in children[J]. Infect Dis Ther, 2018, 7(1):87-120. DOI:10. 1007/s40121-018-0188-z.
[31]Zheng X, Gao L, Wang L, et al. Discovery of ziresovir as a potent, selective, and orally bioavailable respiratory syncytial virus fusion protein inhibitor[J]. J Med Chem,2019, 62(13):6003-6014. DOI:10. 1021/acs.jmedchem. 9b00654.
[32]Zhao S, Shang Y, Yin Y, et al. Ziresovir in hospitalized infants with respiratory syncytial virus infection[J]. N Engl J Med, 2024, 391(12):1096-1107. DOI:10. 1056/NEJMoa2313551.
[33]Cockerill GS, Angell RM, Bedernjak A, et al.Discovery of sisunatovir(RV521), an inhibitor of respiratory syncytial virus fusion[J]. J Med Chem,2021, 64(7):3658-3676. DOI:10. 1021/acs.jmedchem. 0c01882.
[34]Tian L, Pang Z, Li M, et al. Molnupiravir and its antiviral activity against COVID-19[J]. Front Immunol, 2022, 13:855496. DOI:10. 3389/fimmu. 2022. 855496.
[35]Ahmad A, Eze K, Noulin N, et al. EDP-938, a respiratory syncytial virus inhibitor, in a human virus challenge[J]. N Engl J Med, 2022, 386(7):655-666.DOI:10. 1056/NEJMoa2108903.
[36]Sevendal ATK, Hurley S, Bartlett AW, et al.Systematic review of the efficacy and safety of RSVspecific monoclonal antibodies and antivirals in development[J]. Rev Med Virol, 2024, 34(5):e2576.DOI:10. 1002/rmv. 2576.
[37]Fafi I, Levy C, Birgy A, et al. Impact of RSV immunization on the rate of pediatric acute otitis media:a time-series analysis[J]. Clin Infect Dis, 2025:ciaf564. DOI:10. 1093/cid/ciaf564.
[38]Baccelli F, Gottardi F, Muratore E, et al. Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children:a systematic review and individual patient data meta-analysis[J]. Bone Marrow Transplant, 2024, 59(6):765-776. DOI:10. 1038/s41409-024-02252-z.
[39]Chen L, Shi M, Deng Q, et al. A multi-center randomized prospective study on the treatment of infant bronchiolitis with interferon α1b nebulization[J]. PLoS One, 2020, 15(2):e0228391. DOI:10. 1371/journal.pone. 0228391.
基本信息:
中图分类号:R725.6
引用信息:
[1]刘军,刘铁陵,唐洪.呼吸道合胞病毒感染的预防和治疗策略研究进展[J].病毒学报().
2026-07-03
2026-07-03
2026-07-03